Chronic Pruritus Therapeutics Market Report 2026

Chronic Pruritus Therapeutics Market Overview

• Chronic Pruritus Therapeutics market size has reached to $10.91 billion in 2025 • Expected to grow to $15.33 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Rising Healthcare Expenditure Accelerating Adoption Of The Market Due To Improved Access And Investment In Advanced Treatments • Market Trend: Innovative IV Injection Therapies Drive Advancements In The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Chronic Pruritus Therapeutics Market?

Chronic pruritus therapy refers to treatments aimed at managing or alleviating persistent itching (pruritus) that lasts for six weeks or more. Chronic pruritus is managed with a combination of therapies that are tailored to the specific underlying cause, and treatment can be adjusted based on how the patient responds. The main product types in the chronic pruritus therapeutics are corticosteroids, antihistamines, local anesthetics, counterirritants, immunosuppressants, calcineurin inhibitors, and other product types. Corticosteroids are medications that reduce inflammation and itching by suppressing the immune system's response, making them effective in treating chronic pruritus and inflammatory skin conditions. These products are used for various diseases such as atopic dermatitis, allergic contact dermatitis, urticaria, and other conditions. They are distributed through various channels, including hospital pharmacies, drug stores and retail pharmacies, and online providers.

What Is The Chronic Pruritus Therapeutics Market Growth Forecast?

The chronic pruritus therapeutics market size is expected to see strong growth in the next few years. It will grow to $15.33 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to increasing biologic drug approvals, rising investment in dermatology research pipelines, growing focus on immune-mediated itch mechanisms, expansion of online pharmacy access, increasing patient demand for long-term relief solutions. Major trends in the forecast period include increasing adoption of targeted biologic therapies, rising focus on personalized pruritus treatment approaches, growing development of novel anti-itch molecules, expansion of combination therapy protocols, enhanced emphasis on long-term symptom management.

What Is The Driver Of The Chronic Pruritus Therapeutics Market?

The rising healthcare expenditure is expected to propel the growth of the chronic pruritus therapeutics market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come at higher costs, leading to greater overall spending in healthcare. Rising healthcare expenditure supports chronic pruritus therapeutics by improving patient access to dermatology care, enabling the adoption of advanced treatment options, and facilitating greater investment in innovative therapies. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the rising healthcare expenditure is driving the growth of the chronic pruritus therapeutics industry.

Key Players In The Global Chronic Pruritus Therapeutics Market

Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Incyte Corporation, Cipla Limited, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.

Global Chronic Pruritus Therapeutics Market Trends and Insights

Major companies operating in the chronic pruritus therapeutics market are focusing on development of innovative formulations such as intravenous (IV) injection to enhance treatment efficacy and provide faster relief for patients. Intravenous (IV) injection helps treat pruritus by delivering medications, such as antihistamines or corticosteroids, directly into the bloodstream to quickly alleviate itching and reduce inflammation. For instance, in September 2023, Cara Therapeutics Inc., a US-based company that manufactures therapeutics announced that its partner company Maruishi Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company received the approval for Korsuva IV injection syringe, a treatment for pruritus in hemodialysis patients by the Japan's Ministry of Health, Labour and Welfare, a Japan-based government agency. This approval was based on positive Phase 3 clinical trial results conducted by Maruishi in collaboration with Kissei Pharmaceutical Co., Ltd. The treatment showed significant improvements in itching scores compared to a placebo, and it was well-tolerated by patients. The approval also triggers a $1.5 million milestone payment to Cara Therapeutics, the developer of Korsuva, as per the terms of their licensing agreement with Maruishi.

What Are Latest Mergers And Acquisitions In The Chronic Pruritus Therapeutics Market?

In May 2024, Incyte Corporation, a US-based biopharmaceutical company, acquired Escient Pharmaceuticals for $750 million. With this acquisition, Incyte aims to enhance its Inflammation and Autoimmunity (IAI) pipeline by integrating innovative therapies targeting severe inflammatory diseases. Escient Pharmaceuticals Inc. is a US-based biotechnology company that specializes in providing therapeutics for uremic pruritus.

What Defines the Chronic Pruritus Therapeutics Market?

The chronic pruritus therapeutics market consists of sales of capsaicin creams, jak inhibitors, systemic therapies, phototherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Chronic Pruritus Therapeutics Market Report 2026?

The chronic pruritus therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the chronic pruritus therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.